Friedman, Gregory K.
Bernstock, Joshua D. http://orcid.org/0000-0002-7814-3867
Chen, Dongquan
Nan, Li
Moore, Blake P.
Kelly, Virginia M.
Youngblood, Samantha L.
Langford, Catherine P.
Han, Xiaosi
Ring, Eric K.
Beierle, Elizabeth A.
Gillespie, G. Yancey
Markert, James M.
Article History
Received: 3 July 2018
Accepted: 4 September 2018
First Online: 17 September 2018
Competing Interests
: Drs Markert and Gillespie are founders of and own stock and stock options (<8% interest) in Aettis, Inc., a biotech company that has licensed M032 HSV from The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham. Dr. Gillespie currently serves as one of five unpaid members of the Board of Directors for Aettis, Inc. Dr. Gillespie is a founder of and owns stock and stock options (<10%) in Maji Therapeutics, which is developing other HSVs that are not the subject of the current investigation. Drs Markert and Gillespie were also founders of and owned stock and stock options (<8%) in Catherex Inc., a biotechnology company that had licensed additional intellectual property related to oHSV. Catherex, Inc., was sold to Amgen, Inc., on December 18, 2015, and they no longer participate in any decision making or have any control of any aspect of Catherex or Amgen, although they did receive proceeds from the sale of the company. Dr. Gillespie has served as a paid advisor to the Program Project at the Ohio State University that seeks to find improved methods for application of distinct oHSV to treat localized and metastatic cancers. This is generally, but not specifically, related to the subject matter of this investigation.